StockTipsArenaBeta

BUY Lupin Limited — Arun Kumar Mantri

BUYLupin Limited
Lupin share price target & all analyst calls

byArun Kumar MantriHorizon: NA (inferred Swing (≤2wk))9 Nov 2026via CNBC Awaaz.

Entry₹2,025Inferred
Target₹2,062
Total upside +1.83% (call closed)
Stop loss₹2,000-1.23% risk
Exit₹2,00011 Nov 2026, 9:40 am
Stop-loss hit-1.23%
Follow Arun Kumar Mantri for new calls(26% target hit, 213 closed calls)Get alertsWatch LUPIN for new buy/sell callsGet alertsSee 1 active Swing call on LUPINSee 282 active Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 11 Nov 2026
6 supporting3 neutral4 opposing
Supports the BUY call (6)

Lupin launches HIV drug in US, secures eligibility for 180-day generic exclusivity

NewsCnbc-Tv18·3 Nov · 1w ago

(opens in new tab)

Lupin has launched Raltegravir Tablets (600 mg) in the United States market.

BSE · Company Update·3 Nov · 1w ago

(opens in new tab)

Lupin gets USFDA nod for amifampridine tablets, eligible for 180-day generic exclusivity

NewsCnbc-Tv18·2 Nov · 1w ago

(opens in new tab)

Lupin received U.S. FDA approval for Amifampridine tablets.

BSE · Company Update·2 Nov · 1w ago

(opens in new tab)

1 other SEBI-registered advisor has an active swing BUY call on this stock, issued in the last 14 days

Advisor consensus · same horizon·30 Oct · 2w ago

Neutral / worth noting (3)

Lupin shares in focus after US sales beat expectations but profitability impacted

NewsCnbc-Tv18·4 Nov · 1w ago

(opens in new tab)

Lupin Ltd reported unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026.

BSE · Board Meeting·4 Nov · 1w ago

(opens in new tab)

Lupin Limited reported its unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026.

NSE · Outcome of Board Meeting·4 Nov · 1w ago

(opens in new tab)
Weighs against the BUY call (4)

Broker’s Call: Lupin (Accumulate)

NewsHbl·5 Nov · 5d ago

(opens in new tab)

Lupin Q2 Review: Jefferies Cuts Target 15%, Flags US Competition; Kotak Retains Add

NewsNdtv-Profit·5 Nov · 6d ago

(opens in new tab)

Lupin reported Q2 FY2027 results with a 21.8% YoY decline in profit for the period to INR 11,553 Mn and a 10.7% decline in EBITDA to INR 21,712 Mn.

BSE · Company Update·4 Nov · 1w ago

(opens in new tab)

Lupin Limited reported Q2 FY2027 financial results showing a 22.2% year-on-year decline in Profit After Tax (PAT) to INR 11,553 million and a 10.7% decline in EBITDA.

NSE · Press Release·4 Nov · 1w ago

(opens in new tab)

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Lupin

All analyst calls on Lupin

More from Arun Kumar Mantri

Every call and its outcome